Arrowhead Pharmaceuticals (ARWR) Accumulated Expenses (2010 - 2026)

Arrowhead Pharmaceuticals' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• Quarterly Accumulated Expenses rose 22.59% year-over-year to $20.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.4 million (up 22.59% YoY) and the FY2025 annual result came in at $26.9 million, up 22.31% from the prior year.
• Accumulated Expenses was $20.4 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $14.3 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $48.2 million in Q4 2022 and bottomed at $8.8 million in Q4 2023.
• A 5-year average of $27.0 million and a median of $23.7 million in 2022 frame the typical range for Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 790.87% — and 2023, when it tumbled 81.78%.
• Arrowhead Pharmaceuticals' Accumulated Expenses stood at $48.2 million in 2022, then plunged by 81.78% to $8.8 million in 2023, then climbed by 28.46% to $11.3 million in 2024, then gained by 26.56% to $14.3 million in 2025, then soared by 42.72% to $20.4 million in 2026.
• Business Quant data shows ARWR's Accumulated Expenses at $20.4 million in Q1 2026, $14.3 million in Q4 2025, and $26.9 million in Q3 2025.